Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

NCT02203903 is registered in ClinicalTrials.gov with Catherine Bollard as lead sponsor.

NCT NCT02203903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02203903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Lead sponsor
Catherine Bollard
Phase
Phase 1
Overall status
Recruiting
Start date
April 2, 2015
Completion date
June 28, 2027
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory hematopoietic malignancies, acute myeloid leukemia and mds